Benefit of cardiopoietic mesenchymal stem cell therapy on left ventricular remodelling: results from the Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) study.

@article{Teerlink2017BenefitOC,
  title={Benefit of cardiopoietic mesenchymal stem cell therapy on left ventricular remodelling: results from the Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) study.},
  author={John R. Teerlink and Marco Metra and Gerasimos S. Filippatos and Beth A. Davison and Jozef J. Bartunek and Andre Terzic and Bernard J. Gersh and Thomas J. Povsic and Timothy D. Henry and Bertrand Alexandre and Christian Homsy and Christopher R. W. Edwards and Aymeric Seron and William C Wijns and Gad Cotter},
  journal={European journal of heart failure},
  year={2017},
  volume={19 11},
  pages={
          1520-1529
        }
}
AIMS Left ventricular (LV) reverse remodelling is an important marker of improved outcomes in patients with advanced heart failure (HF). We examined the impact of the intramyocardial administration of bone-marrow-derived, lineage-directed, autologous cardiopoietic mesenchymal stem cells (C3BS-CQR-1) on LV remodelling in patients with advanced HF enrolled in the CHART-1 study. METHODS AND RESULTS Patients (n=351) with symptomatic advanced HF secondary to ischaemic heart disease, and reduced LV… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 5 times over the past 90 days. VIEW TWEETS
8 Citations
26 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 26 references

Similar Papers

Loading similar papers…